Carolyn Waite Federici

Carolyn Waite Federici is a seasoned professional in global oncology medical affairs, currently serving as the Director of Global Oncology Medical Affairs Strategy at Daiichi Sankyo, Inc. since July 2021. Carolyn has led medical affairs indication strategies for datopotamab deruxtecan (Dato-DXd) and previously for ifinatamab deruxtecan (I-DXd). Prior experience includes serving as Associate Director at Daiichi Sankyo, Associate Director of Global Scientific Engagement at Lockwood, and multiple roles at Invicro, Avant Healthcare, and AdMed, where Carolyn developed medical content across various therapeutic areas and mentored junior staff. Carolyn began the career with a research background, holding positions as a research analyst, adjunct chemistry instructor, and a research associate at Rutgers University, where Carolyn completed a Ph.D. in Chemical and Biochemical Engineering. Carolyn also gained experience in bioprocess development at Johnson & Johnson.